Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.64 |
| ▸ | GSK3B | P49841 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GSK3A | P49840 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | HRH2 | P25021 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12468948 | 0.94 | GSK3B (0.56) | HRH3GSK3BGAAMAPTKCNH2 | |
| SCHEMBL12468821 | 0.87 | HRH3 (0.66) | HRH3GSK3BMAPTTSHRKMT2A | |
| SCHEMBL12469067 | 0.86 | HRH3 (0.61) | HRH3MAPTPOLBSIGMAR1 | |
| SCHEMBL12469429 | 0.83 | HRH3 (0.64) | HRH3GSK3BMAPT | |
| SCHEMBL12468897 | 0.81 | HRH3 (0.68) | HRH3GSK3BMAPK1GSK3A | |
| SCHEMBL12468760 | 0.81 | HRH3 (0.56) | HRH3GSK3BMAPTTSHRKMT2A | |
| SCHEMBL12468740 | 0.80 | TP53 (0.57) | HRH3GSK3BMAPTTSHRPOLB | |
| SCHEMBL12469133 | 0.79 | HRH3 (0.64) | HRH3GSK3BMAPTMAPK1GSK3A | |
| SCHEMBL12469545 | 0.77 | HRH3 (0.55) | HRH3GSK3BMAPTTSHRKMT2A | |
| SCHEMBL15431854 | 0.75 | HRH3 (0.61) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289047-A1 | HETEROARYLTHIO DERIVATIVES AND ANALOGUES | EPIOMED THERAPEUTICS, INC. (US) | 2013-10-31 | — | — | US | disclosed |
| WO-2012051601-A2 | HETEROARYLTHIO COMPOUNDS | EPIOMED THERAPEUTICS, INC. (US) | 2012-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289047-A1 | HETEROARYLTHIO DERIVATIVES AND ANALOGUES | NLN, HTT, ABAT | HRH3 1812/4885GSK3B 2922/4885GAA 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.